Clinical Trial Update: Dapagliflozin in Pulmonary Arterial Hypertension [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dapagliflozin for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Thromboembolic Pulmonary Hypertension

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: Mads Ersbøll | Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension | Phase 2 | Status: COMPLETED